A strategic vision for R&D into point-of-care testing in resource-poor settings Tuberculosis (TB) remains a major challenge to public health globally, particularly in resource-poor settings. August 2011 – Although most cases of TB are curable, tuberculosis causes around 2 million…
On November 12, 2010, the Treatment Action Campaign (TAC) and partners jointly sent an open letter to Cepheid calling for affordable and expanded access to the GeneXpert® MTB/RIF TB diagnostic test. Following this correspondence, TAC and partners had a teleconference with FIND and Cepheid, during which Cepheid indicated that prices for the GeneXpert would be reduced. During December, FIND announced that it had negotiated a volume-based price reduction agreement with Cepheid, lowering the cost of the GeneXpert.
The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
The global response to help countries scale up treatment of multidrug-resistant tuberculosis (MDR-TB) is underfunded and ineffective, according to a new report released today by three medical and medical advocacy organisations. A 20-month effort to reform the Green Light Committee Initiative, a World Health Organization (WHO)-hosted programme designed to help countries gain technical support for scale up of MDR-TB and access to quality-assured MDR-TB drugs, needs to be closely monitored to see if the reforms will address many key bottlenecks.
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…
A new rapid test for tuberculosis (TB) which was just recommended by the World Health Organization (WHO) for widespread use has the potential to revolutionize the world’s fight against the disease, said the Treatment Action Group today,
From The Lancet, Volume 376, Issue 9749, Pages 1283 - 1284, 16 October 2010 Salmaan Keshavjee,a,b,c Francoise Girard,d Mark Harrington,e Paul E Farmera,b,c Tuberculosis—a curable infectious disease—continues to cause illness in more than 9 million people annually. In the past…
HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, Immune-based therapies, and Preventive Technologies in Development. By Polly Clayden, Lei Chou, Simon Collins, Mark Harrington, Richard Jefferys, Eleonora Jimenez, Scott Morgan, Tracy Swan, Javid Syed and Claire Wingfield.
2009 TB Research Funding Trends, 2005 - 2008 - Second Edition March 2010 - This is an update to Treatment Action Group’s 2009 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through…